Dow Jones 30 Stocks SEC Filings — May 20, 2026

20-05-2026

Red Cat Holdings, Inc. (RCAT) completed the acquisition of Quaze Technologies Inc., a developer of wireless power transfer technology for unmanned systems, on May 20, 2026. The acquisition addresses a key operational constraint—manual battery swaps and connector-based charging—by enabling autonomous recharging across air, land, and maritime domains. Quaze will operate as an independent business unit and maintain a platform-agnostic model, opening a new revenue channel from third-party systems while strengthening Red Cat's all-domain capabilities.

• · Quaze is based in Québec, Canada.
• · The QU6 electronic architecture enables large surfaces to function as wireless energy access points without requiring precise alignment, physical connectors, or direct contact.
• · The system can operate in the presence of debris, sand, ice, or snow.
• · Quaze’s technology has been demonstrated across aerial drones, ground systems, and autonomous underwater vehicles.
• · Red Cat expects Quaze to support expansion into maritime systems and multi-platform autonomy, including swarming, extended ISR missions, and autonomous deployment cycles.
• · The acquisition introduces a new revenue channel through integration into third-party systems, making Quaze a potential standard for wireless power across the unmanned systems ecosystem.

20-05-2026

Analog Devices Inc. (ADI) reported a strong Q2 FY2026 with revenue of $3.62B, up 37% YoY from $2.64B, and net income of $1.18B, more than doubling from $570M. The Industrial segment surged 56% YoY and Communications grew 79%, while Automotive revenue was nearly flat at +2% YoY. The company also recorded $29.1M in new employee severance costs under global repositioning actions during the quarter.

• · Distributor channel revenue was $2.07B (57% of total) in Q2 FY2026, up from $1.48B (56%) in Q2 FY2025.
• · Direct customer revenue was $1.52B (42% of total) in Q2 FY2026, up from $1.13B (43%) in Q2 FY2025.
• · Accrued special charges for global repositioning actions stood at $13.4M at May 2, 2026, down from $31.2M at January 31, 2026, after $17.9M in severance payments during Q2.
• · Total assets measured at fair value were $2.23B as of May 2, 2026, including $703M in government/institutional money market funds and $398M in corporate obligations (Level 2).
• · Total liabilities measured at fair value were $33.9M, consisting of forward foreign currency exchange contracts ($10.0M) and interest rate derivatives ($23.9M).
• · Other comprehensive income for Q2 FY2026 was $2.3M, driven by foreign currency translation gains ($1.3M) and derivative gains ($0.6M).
• · Provision for income taxes increased to $148.5M in Q2 FY2026 from $56.2M in Q2 FY2025, reflecting higher pre-tax income.

20-05-2026

V F Corp reported Q4 FY26 revenue of +1% YoY (or +3% C$ ex-Dickies), ahead of guidance of flat to +2% C$, driven by strong Americas growth (+10% C$ ex-Dickies). Adjusted operating income of $54M exceeded guidance of $10M-$30M, while gross margin expanded 240bps to 56.4%. However, Vans brand revenue declined 1% (or -5% C$) and EMEA region revenue fell 5% C$ ex-Dickies. Full-year FY26 revenue grew 1% YoY, with adjusted operating margin up 110bps to 7.0% ex-Dickies, and net debt reduced 16% to $4.2B, bringing leverage down to 3.1x from 4.1x a year ago. FY27 guidance calls for continued revenue growth of +1% to +2% C$ and adjusted operating margin of approximately 8%.

• · Q4 FY26 Americas region revenue ex-Dickies grew +10% C$, the highest growth since Q1'23.
• · Vans Americas DTC returned to growth for the first time in over four years.
• · The North Face delivered its fifth consecutive quarter of double-digit footwear growth.
• · Timberland opened 11 full-price stores in the Americas as of Q4 FY26.
• · Altra brand grew approximately 50% in Q4 FY26.
• · FY26 free cash flow of $405M excludes $100M net impact of pension termination.
• · FY27 guidance: Vans expected to be down mid-single digits with improving trends.
• · Adjusted amounts exclude Reinvent costs (~$8M in Q4, $44M FY26), Dickies transaction costs ($10M) and gain ($127M), pension settlement charges ($158M Q4, $192M FY26), pension excise tax ($25M), and Napapijri goodwill impairment ($31M).
• · Combined adjustments negatively impacted EPS by $0.30 in Q4 FY26 and $0.20 in FY26.

20-05-2026

ChoiceOne Financial Services, Inc. held its 39th Annual Shareholder Meeting on May 20, 2026, presenting financial results and strategic updates. The company reported total assets of $4.4B, deposits of $3.7B, and gross loans of $3.0B as of March 31, 2026. Adjusted net income grew to $28.2M in 2025 from $26.7M in 2024, while adjusted basic EPS rose to $3.70 from $3.40. However, Q1 2026 adjusted net income dropped sharply to $1.0M, and adjusted basic EPS fell to $0.91, reflecting a significant decline from the prior year.

• · The company has 54 locations throughout Michigan.
• · Community donations exceeded $604,000 and volunteer hours exceeded 8,000 as of December 31, 2025.
• · The merger with Fentura Financial Inc. added $1.8B in assets, $1.4B in loans, $1.4B in deposits, and $193M in equity in 2025.
• · Cash dividends per share increased steadily from $0.94 in 2021 to $1.13 in 2025, with a dividend yield of 3.8% as of December 31, 2025.
• · The company's mobile app has a 4.7-star rating on the Apple App Store.
• · ChoiceOne was recognized as SBA Michigan 504 Third Party Lender of the Year for fiscal year 2023 and received the MBA Innovator of the Year award in 2025.

20-05-2026

Securitize reported Q1 2026 revenue of $19.5M, up 39% YoY and the highest quarterly revenue in company history, driven by growth in tokenized asset services. However, Adjusted EBITDA fell sharply to $0.8M from $4.1M in the prior year, and net loss widened to $7.9M ($0.88 per diluted share). The company also highlighted key partnerships with NYSE, Uniswap Labs, and Computershare, and noted the pending business combination with Cantor Equity Partners II (CEPT) is expected to close in H1 2026.

• · Net loss per diluted share was $0.88 in Q1 2026.
• · Average AUM in Q1 2026 was $3.2B, with AUM of $3.4B as of March 31, 2026.
• · Aggregated Transaction Volume in Q1 2026 was $1.9B.
• · 650 active funds were serviced by Securitize Fund Services as of March 31, 2026.
• · AUA was $24.9B as of March 31, 2026.
• · The tokenized real-world asset market grew from ~$23B (Dec 31, 2025) to $31B (Mar 31, 2026), ~35% growth.
• · Securitize was named design partner and first digital transfer agent for the NYSE Digital Trading Platform.
• · Securitize was chosen to tokenize loan interests tied to Trump International Hotel & Resort, Maldives.
• · The business combination with CEPT is expected to close in H1 2026, subject to regulatory and shareholder approvals.
• · Securitize ended Q1 2026 with approximately breakeven operating cash flow before working capital movements and public-company related expenses.

20-05-2026

Longeveron Inc. filed a definitive proxy statement (DEF 14A) for its 2026 Annual Meeting of Stockholders to be held virtually on July 1, 2026. Key proposals include electing three directors, increasing authorized Class A common stock, authorizing a reverse stock split (1:2 to 1:20), amending the 2021 Incentive Award Plan to increase authorized shares, and ratifying CBIZ CPAs P.C. as independent auditor for fiscal year 2026. The filing does not disclose financial results or performance metrics, so no positive or negative trends can be assessed from this document alone.

• · Record date for voting is May 11, 2026.
• · Class A common stock holders have 1 vote per share; Class B common stock holders have 5 votes per share.
• · A quorum requires at least one-third of issued and outstanding shares representing a majority of votes entitled to be cast.
• · Proposal 2 seeks to increase authorized Class A common stock shares (amount not specified).
• · Proposal 3 authorizes a reverse stock split at a ratio ranging from 1:2 to 1:20, with exact ratio set by the Board.
• · Proposal 4 seeks to increase shares authorized under the 2021 Incentive Award Plan (amount not specified).
• · Proposal 6 allows adjournment if needed to solicit additional votes for Proposals 2 or 3.

20-05-2026

Willamette Valley Vineyards, Inc. appointed John Hazlett as Chief Financial Officer effective May 20, 2026, replacing John Ferry who announced his retirement on February 12, 2026. Mr. Hazlett will receive a base salary of $216,000 per year and is eligible for an annual performance-based incentive of up to $24,000. The transition period for Mr. Ferry has not yet been determined.

• · Mr. Hazlett, 51, has served as founding partner of Trailwise Advisory Services since January 2025.
• · He previously served as CFO of RENA Technologies North America (Dec 2021–Dec 2024) and Climax Portable Machine Tools (Mar 2018–Mar 2020).
• · He holds an MBA from Baldwin Wallace University and a BS in Accounting and Finance from Bowling Green State University, and maintains an active CPA license in Ohio.
• · Mr. Hazlett has no family relationships with any current director, director nominee, or executive officer of the Company.
• · The employment agreement is dated May 19, 2026, and performance goals will be established annually by the Company’s President.

20-05-2026

NanoViricides, Inc. (NNVC) announced a registered direct offering of approximately $2 million with a single institutional investor, involving 1,333,334 common shares (or pre-funded warrants) and accompanying warrants exercisable at $1.75 per share for three years. The offering is expected to close on May 18, 2026, with D. Boral Capital LLC as placement agent. While the capital raise provides near-term funding, the relatively small gross proceeds of ~$2 million highlight the company's ongoing need for additional capital to support clinical-stage operations.

• · Each whole warrant has an exercise price of $1.75 per share and expires three years from issuance.
• · The offering is conducted under an effective shelf registration statement on Form S-3 (Registration No. 333-271706), declared effective on May 22, 2023.
• · NV-387 has received Orphan Drug Designation from the FDA, potentially providing 7 years market exclusivity, tax credits, and fee exemptions upon approval.
• · NV-387 has shown efficacy in lethal animal infection models for Influenza, RSV, Coronaviruses, Monkeypox, Smallpox, and Measles.

20-05-2026

KonaTel, Inc. reported a net loss of $282,590 for Q1 2026, a significant improvement from the $917,528 net loss in Q1 2025. Revenue declined 12.2% to $1,905,062 from $2,168,714 in the prior year period, but gross profit improved 23.6% to $805,604 due to a sharp reduction in cost of revenue. The company's cash position decreased to $665,068 from $704,867 at year-end 2025, and total stockholders' equity fell to $196,220 from $384,205.

• · Operating loss improved to $281,215 from $929,645 in Q1 2025, a 69.7% improvement.
• · Cost of Revenue decreased 27.5% to $1,099,458 from $1,516,821, driving the gross profit improvement despite lower revenue.
• · Payroll and Related Expenses decreased 30.9% to $601,643 from $871,362.
• · Stock Option Expense decreased 60.5% to $94,605 from $239,337.
• · Professional and Other Expenses decreased 46.7% to $83,942 from $157,431.
• · Cash used in operating activities was $39,650 in Q1 2026, compared to cash provided by operations of $269,037 in Q1 2025.
• · Accounts Receivable decreased 49.7% to $142,884 from $284,167, providing $121,781 in operating cash flow.
• · Total liabilities increased slightly to $2,090,251 from $2,080,074.
• · The company's accumulated deficit grew to $10,366,733 from $10,084,143.
• · No income tax expense was recorded for either period.

20-05-2026

Farmhouse, Inc. reported a net loss of $155,427 for Q1 2026, compared to net income of $68,288 in Q1 2025, driven by higher operating expenses and the absence of a prior-year gain on debt extinguishment. The company has no revenues, negative stockholders' deficit of $2.82M, and significant liabilities including defaults on notes and related party payables. Cash increased to $32,329 from $14,188 at year-end 2025, but operating cash flow remained negative at ($61,459).

• · The company has no revenues and has never generated revenue.
• · Stockholders' deficit increased to $2.82M from $2.67M at year-end 2025.
• · Accrued payroll and payroll taxes of $1.54M is the largest liability.
• · Convertible notes payable of $113,766 (current) and $443,137 (long-term) are outstanding, with $45,000 in default.
• · Notes payable of $55,000 are in default.
• · Due to related parties of $336,880 includes $4,500 in default.
• · Derivative liabilities from convertible instruments increased to $104,667 from $89,455.
• · Crypto assets of $14,209 were acquired during Q1 2026 for $15,400, with an unrealized loss of $1,191.
• · Loss on derivatives of $14,212 was recognized in Q1 2026.
• · Interest expense increased to $30,575 from $15,853 in Q1 2025.
• · Weighted average shares outstanding increased to 18,999,617 from 17,925,950.
• · Basic and diluted net loss per share was $(0.01) vs $0.00 in prior year.

20-05-2026

Evernorth Holdings Inc. released a detailed communication regarding its proposed business combination with Armada Acquisition Corp. II (SPAC) and Pathfinder Digital Assets LLC, as announced on October 19, 2025. The communication is an educational piece by Chief Business Officer Sagar Shah explaining why RLUSD (a stablecoin) cannot replace XRP in the XRP Ledger's decentralized trading infrastructure, arguing that both assets serve distinct and complementary functions. The filing does not provide financial results, but it reaffirms the forward-looking strategy of building on-chain finance routing infrastructure using XRP, while cautioning that these views are subject to significant uncertainty.

• · The Business Combination Agreement was signed on October 19, 2025, with a Registration Statement (including preliminary proxy statement/prospectus) filed on March 18, 2026, which is not yet effective.
• · Evernorth identifies three structural reasons why RLUSD cannot replace XRP as the routing asset: (1) stablecoins have issuer risk / single point of failure; (2) stablecoins must comply with sanctions, freeze tokens, and restrict jurisdictions, undermining neutrality; (3) liquidity pools on a DEX require two distinct assets, so a non-stablecoin bridge asset is always needed.
• · XRP is cited as having 'years of operating history without interruption', deep liquidity, and no issuer that can censor or freeze the asset — key features for its role as a bridge/collateral/escrow asset.
• · The filing includes a forward-looking statement caveat that there can be no assurance the anticipated development of on-chain finance will occur as expected.

20-05-2026

Cyber Enviro-Tech, Inc. (CETI) filed its 10-K for the year ended December 31, 2025, reporting no revenue for the second consecutive year and a net loss of $7,640,973, which widened 20.0% from a net loss of $6,365,984 in 2024. The company's operating loss increased 9.4% to $3,116,470, while total liabilities rose to $5,090,572 from $4,067,950, and stockholders' deficit deepened to ($3,101,224) from ($502,259). However, cash used in operating activities improved to $2,885,340 from $3,496,740, and the company raised $3,889,289 in financing activities, primarily from convertible notes.

• · Total assets decreased 44.2% from $3,565,691 in 2024 to $1,989,348 in 2025, primarily due to the reclassification of $2,081,952 in assets of discontinued operations to zero.
• · Convertible notes payable (current and non-current) increased from $1,943,484 in 2024 to $2,560,009 in 2025, a 31.7% increase.
• · Derivative liability surged 176.8% from $387,238 in 2024 to $1,071,944 in 2025.
• · Accumulated deficit deepened 58.1% from ($13,129,093) to ($20,753,574).
• · The company had a loss on sale of the Alvey oil field of $1,241,110 in 2025.
• · Non-cash shares issued for conversion of convertible notes and accrued interest totaled $4,139,034 in 2025, up from $1,695,000 in 2024.
• · Debt discount on convertible notes payable was ($1,504,245) in 2025, compared to $337,889 in 2024.
• · The company had $215,000 in loans receivable and $203,368 in investment in WTXR as of December 31, 2025.
• · Contingent liabilities decreased from $437,500 to $190,000.
• · The company had a net change in cash from continuing operations of $17,599 in 2025, compared to ($1,261,668) in 2024.
• · Cash paid for interest was $19,156 in 2025, compared to $0 in 2024.
• · The company had 13,663,352 shares of common stock to be issued as of December 31, 2025, up from 2,973,132 in 2024.
• · Potentially dilutive shares totaled 132,414,568 as of December 31, 2025, up from 97,320,540 in 2024.
• · The company had no revenue and no cost of sales in both 2025 and 2024.

20-05-2026

AITX announced that its subsidiary RAD has signed an agreement with a global healthcare organization. The filing is a Form 8-K furnished under Item 8.01, with the press release attached as Exhibit 99.1. No financial terms or specific performance metrics were disclosed, and the filing is not deemed filed for Exchange Act purposes.

• · The agreement is with a global healthcare organization (name not disclosed).
• · The press release was issued on May 20, 2026.
• · The filing is furnished under Item 8.01 and is not deemed filed under Section 18 of the Exchange Act.

20-05-2026

Avista Corp. issued $160M in first mortgage bonds ($90M at 4.77% due 2029, $70M at 6.10% due 2056) on May 14, 2026, with an additional $70M of 6.10% bonds expected in August 2026, to refinance debt and fund capital expenditures. At the 2026 Annual Meeting, shareholders approved the election of all 11 directors, ratification of Deloitte & Touche as auditor, and an advisory vote on executive compensation; however, a proposal to reduce the shareholder approval threshold from 80% to a majority failed to receive the required 80% affirmative vote.

• · The bonds are secured by a lien on substantially all property of the Company (except excepted property) under the Mortgage and Deed of Trust dated June 1, 1939.
• · The bonds are redeemable prior to maturity at the Company's option with a make-whole premium plus accrued interest; bonds held by specified foreign entities are redeemable at 100% of principal plus accrued interest.
• · Proposal 4 (amendment to reduce shareholder approval requirement from 80% to a majority) failed, receiving 64,317,253 votes for, 805,879 against, and 325,048 abstentions, but not reaching the 80% threshold of outstanding shares.
• · Director Janet D. Widmann received the lowest support among nominees with 58,951,492 votes for and 6,351,486 against.
• · The bonds were issued in the private placement market and are not registered under the Securities Act of 1933.

20-05-2026

Boothe Investment Group, Inc. filed its 13F-HR for the quarter ended March 31, 2026, reporting a total of 40 equity holdings with an aggregate market value of approximately $310.7 million. The portfolio is heavily weighted toward ETFs, with the largest positions in Simplify Exchange Traded Funds Managed Futures ($52.6M), DoubleLine ETF Trust Opportunistic ($31.1M), and WisdomTree Europe Hedged Equity ($23.3M). The filing reflects a diversified mix of large-cap stocks, sector ETFs, and fixed-income ETFs, with no single equity position exceeding 17% of the portfolio.

• · The portfolio includes 40 equity positions with a total market value of $310,691,710.
• · Top 5 holdings by value: Simplify Managed Futures ($52.6M), DoubleLine Opportunistic ($31.1M), WisdomTree Europe Hedged ($23.3M), VictoryShares Small Cap ($18.3M), Global X FTSE ETF ($14.7M).
• · Largest single stock positions: Pfizer ($9.9M), Citigroup ($8.9M), SLB Limited ($8.2M), ServiceNow ($9.9M), and Pinterest ($11.9M).
• · The portfolio has a significant ETF tilt, with 10+ ETF positions covering equity, fixed income, and alternative strategies.
• · Notable holdings include Berkshire Hathaway Class A (2 shares, $1.4M), Microsoft (15,635 shares, $5.8M), and Meta Platforms (9,992 shares, $5.7M).

20-05-2026

Entravision Communications Corp. mutually terminated its Cooperation Agreement with Alexandra Seros and related trusts on May 18, 2026. The agreement had been in place since May 4, 2023, and governed board nomination rights and stock ownership commitments. As a result, all rights and obligations under the agreement have been terminated, but Thomas Strickler (originally nominated under the agreement) will remain on the board. No financial figures are disclosed in this filing.

• · The Cooperation Agreement was originally dated May 4, 2023.
• · The termination is mutual between the Company and the Stockholders.
• · Thomas Strickler will remain on the board despite the termination of the agreement.

20-05-2026

Select Medical Holdings Corp. received a non-binding proposal from Executive Chairman Ortenzio, CEO Chernow, and Jackson to acquire all outstanding shares for $16.00-$16.20 per share in cash, representing a 15% premium. A Special Committee of independent directors was formed to evaluate the proposal. The merger is expected to close in mid-2026, subject to regulatory approvals and stockholder vote.

• · The HSR Act waiting period expired on April 27, 2026.
• · Appraisal rights are available under DGCL for dissenting stockholders.
• · The Special Committee was formed on November 24, 2025.
• · The November Proposal was publicly disclosed via Schedule 13D on November 24, 2025.
• · The Buyer Consortium includes Ortenzio, Jackson, and Welsh Carson funds.
• · The merger is taxable for U.S. federal income tax purposes.

20-05-2026

CorVel Corp reported fiscal year 2026 revenue of $959M (+7% YoY) and EPS of $2.14 (+17% YoY). Q4 revenue was $249M (+7% YoY) with EPS of $0.61 (+20% YoY). The company ended the quarter with $233M cash and no debt, while repurchasing $20.1M of stock. However, gross margin remained flat at 25% and general and administrative expenses decreased slightly.

• · Cash increased from $170.6M to $233.1M YoY.
• · No borrowings outstanding.
• · Stock repurchases of $20.1M during Q4.
• · General and administrative expenses decreased from $24.6M to $23.3M in Q4.
• · Income from operations increased to $39.7M from $33.3M in Q4.
• · Customer deposits increased to $115.7M from $101.5M.
• · Accounts receivable decreased to $101.3M from $104.1M.
• · Property, net increased to $117.9M from $92.1M.
• · Goodwill and other assets decreased to $41.6M from $46.4M.
• · Retained earnings grew to $1,013.4M from $903.1M.

20-05-2026

Cavitation Technologies, Inc. (CVAT) reported a net loss of $219,000 for the three months ended March 31, 2026, compared to a net loss of $230,000 in the same period last year, while revenue collapsed 97.5% to $3,000 from $122,000. For the nine-month period, the company swung to a net loss of $953,000 from net income of $122,000 in the prior year, driven by a 97% revenue decline to $6,000 and the absence of a prior-year $880,000 gain on patent assignment. The company's cash position deteriorated sharply to $45,000 from $249,000 at June 30, 2025, and stockholders' equity turned negative to ($467,000) from $69,000.

• · Total liabilities increased 133.8% to $533,000 from $228,000, driven by new promissory notes payable – related party ($91,000), convertible notes payable ($28,000), and derivative liability ($18,000).
• · Stockholders' equity turned negative to ($467,000) from $69,000 at June 30, 2025.
• · The company raised $173,000 from sale of common stock units and $90,000 from a note payable during the nine months ended March 31, 2026.
• · General and administrative expenses for the nine months increased 12.0% to $949,000 from $847,000, despite a 17.3% decline in the quarter.
• · Research and development expenses were zero in the current quarter, down from $42,000 in the prior-year quarter.
• · The company recorded a $20,000 gain from change in fair value of derivative liability in the current quarter, with no such item in the prior year.
• · Cash used in operating activities improved 15.5% to $527,000 from $624,000 in the prior-year nine-month period.
• · No revenue was generated from cost of revenue in either period, indicating no direct production costs.

20-05-2026

CAVA Group reported revenue of $438.3M for the 16 weeks ended April 19, 2026, up 32.1% from $331.8M in the prior-year period, driven by restaurant revenue growth. However, net income declined to $23.6M from $25.7M, and diluted EPS fell to $0.20 from $0.22, as operating expenses grew faster than revenue. The company also reported an unrealized loss on investments and a decrease in comprehensive income.

• · Restaurant operating expenses increased 32.2% YoY to $327.1M, outpacing revenue growth.
• · General and administrative expenses rose 24.6% YoY to $51.6M.
• · Depreciation and amortization increased 22.4% YoY to $25.5M.
• · Pre-opening costs grew 37.5% YoY to $6.2M.
• · Impairment and asset disposal costs surged 63.1% YoY to $2.7M.
• · Interest income, net decreased 11.6% YoY to $4.1M.
• · The company invested $5.0M in a convertible promissory note during the period.
• · Cash paid for income taxes was $0.3M, down from $1.3M in the prior year.
• · CAVA Rewards and gift card liabilities decreased to $5.9M from $6.8M at the start of the period.
• · Total assets increased 4.6% to $1.42B from $1.36B at year-end 2025.
• · Accumulated deficit improved to $(230.0M) from $(253.6M) at year-end 2025.
• · The company had an unrealized loss on investments of $0.1M (net of tax) in the current period.

20-05-2026

Innventure, Inc. regained compliance with Nasdaq Listing Rule 5605(c)(2)(A) after appointing Bruce Brown to the Audit Committee, restoring it to three independent members. Nasdaq confirmed compliance on May 19, 2026, resolving the prior deficiency caused by Daniel Hennessy's resignation.

• · Daniel Hennessy resigned from the Board and Audit Committee effective April 29, 2026.
• · The Company notified Nasdaq of non-compliance on April 30, 2026.
• · Bruce Brown was appointed to the Audit Committee on May 15, 2026.
• · Nasdaq confirmed compliance on May 19, 2026.

20-05-2026

Salesforce filed a DEFA14A proxy supplement on May 20, 2026, urging stockholders to vote FOR Proposal 2 to amend and restate the 2013 Equity Incentive Plan, adding 34 million shares. The supplement addresses ISS's recommendation against the proposal due to a formulaic SVT calculation, which was negatively impacted by Salesforce's $25 billion accelerated share repurchase program that reduced shares outstanding. While ISS supports other proposals and Glass Lewis supports Proposal 2, the company argues the share repurchase has already retired 103 million shares—more than three times the requested shares—resulting in a net reduction in shares outstanding and a reasonable pro-forma equity overhang of 15.7%.

• · ISS supports all director nominees and the say-on-pay proposal but recommends against Proposal 2 due to a formulaic SVT calculation.
• · Glass Lewis & Co. is supporting Proposal 2.
• · The share repurchase program reduced shares outstanding, causing the same share reserve to represent a larger percentage of a smaller equity base, which ISS's SVT model penalizes.
• · The company states that without the share increase, it may need to significantly increase cash compensation, potentially misaligning employee and stockholder interests.
• · The 2013 Plan includes broad-based participation, with 96% of equity awards granted to non-executive officers in fiscal 2026.
• · The company's three-year average burn rate is 1.5%.

20-05-2026

Dorian LPG reported strong Q4 FY2026 results with revenues of $153.3M (up 102% YoY) and net income of $81.0M ($1.90 EPS), compared to $8.1M ($0.19 EPS) in Q4 FY2025. For the full fiscal year, revenues were $481.5M (up 36.3% YoY) and net income was $193.7M ($4.54 EPS), versus $90.2M ($2.14 EPS) in FY2025. The company declared an irregular cash dividend of $1.00 per share ($42.8M) and completed the sale of the VLGC Cobra for $81.9M. However, general and administrative expenses increased significantly by 60.9% in Q4 and 24.4% for the full year, and interest income declined.

• · The Baltic LPG Index averaged $90.453 in Q4 FY2026 vs $51.715 in Q4 FY2025, a 75% increase.
• · Available days for the fleet increased from 8,776 in FY2025 to 9,113 in FY2026.
• · Chartered-in fleet expanded from four to six vessels, increasing chartered-in days from 1,460 to 1,923 in FY2026.
• · Unrealized gain on derivatives was $0.6M in Q4 FY2026 vs a loss of $2.6M in Q4 FY2025.
• · Realized gain on derivatives decreased to $0.3M in Q4 FY2026 from $1.1M in Q4 FY2025.
• · Average SOFR rate on the 2023 A&R Debt Facility was lower in Q4 FY2026 compared to Q4 FY2025.
• · The company prepaid $16.5M of the 2023 A&R Debt Facility related to the sold VLGC Cobra.

20-05-2026

S&P Global Inc. announced the pricing of a private offering of $2.0 billion aggregate principal amount of senior notes by Mobility Global Inc., a holding company for its Mobility division, ahead of the planned spin-off. The offering includes $650 million of 5.050% notes due 2029, $650 million of 5.450% notes due 2031, and $700 million of 6.050% notes due 2036, with closing expected on May 29, 2026. The notes are being offered to qualified institutional buyers and non-U.S. persons in exempt transactions.

• · The offering is exempt from registration under Rule 144A and Regulation S.
• · The notes are being issued by Mobility Global Inc., a recently formed holding company for the Mobility division.
• · The spin-off of the Mobility division is intended to be completed via a distribution to S&P Global shareholders.
• · The press release was issued pursuant to Rule 135c of the Securities Act.

20-05-2026

First Real Estate Investment Trust of New Jersey, Inc. has filed a preliminary proxy statement (PREM14A) seeking stockholder approval of a Plan of Complete Liquidation and Dissolution. The filing details the proposed winding-up, sale of all assets, and estimated liquidating distributions, but emphasizes significant uncertainties regarding timing and final amounts. Key risk factors include potential delays in asset sales, transaction costs, tenant defaults, REIT qualification risks, and possible 100% excise tax on prohibited transactions, all of which could reduce or delay distributions to stockholders.

• · All asset sale proceeds are contingent; estimated liquidating distribution ranges are mentioned but no specific figures provided.
• · If REIT status is lost, the Trust would be taxed at corporate rates and could no longer deduct distributions, reducing funds available.
• · Prohibited transaction sales could result in a 100% excise tax on net gains from such sales.
• · The Trust may provide financing to buyers (purchase money obligations), delaying cash distributions to stockholders.
• · The Board reserves the right to delay, amend, or modify the Plan of Liquidation without further stockholder approval.
• · A reserve fund may be established for contingent claims, which could further delay or reduce distributions.
• · Closing conditions, buyer defaults, and inability to find buyers at expected prices are identified as risks.
• · Occupancy rates, tenant defaults, and lower-than-expected rental income during liquidation could reduce final distributions.
• · The filing includes no prior-period financial comparisons or numerical performance metrics.

20-05-2026

On May 15, 2026, Bed Bath & Beyond appointed CFO Brian LaRose as principal accounting officer, succeeding Leah Putnam, and appointed Tamara Ward as a new director, effective immediately. Ms. Ward will chair the Compensation Committee and serve on the Audit Committee, receiving an annual cash retainer of $75,000 and restricted stock units valued at $165,000. No financial performance metrics or period-over-period comparisons are included in this filing.

• · Brian LaRose's appointment as principal accounting officer is effective May 15, 2026, with no arrangements or understandings with any other person.
• · Tamara Ward's term as director expires at the 2027 annual meeting or earlier upon death, resignation, or removal.
• · Ms. Ward will enter into the Company's standard form of indemnification agreement.
• · No family relationships or material interests in transactions were reported for either appointee.

20-05-2026

Innovative Industrial Properties closed four secured term loans totaling $44.9 million in gross proceeds, with a five-year term and a fixed interest rate of 6.67%. The proceeds will be used to repay unsecured notes maturing at the end of May 2026, reflecting the company's focus on maintaining a strong balance sheet and extending its debt maturity profile.

• · The loans are secured by certain properties of the Company.
• · The loans have an initial term of five years.
• · The proceeds will be used to pay off unsecured notes maturing at the end of May 2026.
• · The financing establishes a new lending relationship for the company.

20-05-2026

Roivant Sciences reported financial results for Q4 and fiscal year ended March 31, 2026, highlighting a $2.25 billion global settlement with Moderna and a $770.2 million gain on litigation settlement. The company reported consolidated cash of $4.3 billion and income from continuing operations of $355.7 million in Q4, compared to a loss of $252.4 million in the prior-year quarter. However, R&D expenses rose 37% to $198.9 million in Q4, and non-GAAP loss from continuing operations widened to $222.7 million from $154.4 million, reflecting increased spending on the anti-FcRn franchise and discontinuation of batoclimab.

• · IMVT-1402 showed ACR20/50/70 response rates of 72.7%, 54.5%, and 35.8% at Week 16 in D2T RA; among patients who failed JAK and anti-TNF inhibitors (N=107), rates were 72.0%, 53.3%, and 37.4%.
• · Brepocitinib NDA in DM accepted with Priority Review; target action date in Q3 2026; commercial launch expected by end of September 2026.
• · Brepocitinib Phase 2 BEACON in CS achieved 22.3-point improvement in mean CSAMI-A at Week 16 vs 0.7-point improvement for placebo; Breakthrough Therapy Designation granted.
• · Mosliciguat Phase 2 PHocus study enrolled 135 subjects within one year; topline data expected H2 2026.
• · Batoclimab Phase 3 TED studies did not meet primary endpoint; development discontinued across all indications.
• · Genevant lawsuit against Pfizer/BioNTech: claim construction ruling issued September 2025, terms construed favorably per Genevant.
• · FY2026 loss from continuing operations improved to $397.9M from $729.8M in FY2025, a 45.5% reduction.
• · Non-GAAP loss from continuing operations widened to $222.7M in Q4 FY2026 from $154.4M in Q4 FY2025.
• · FY2026 G&A expenses increased 3.2% to $610.5M, but non-GAAP G&A expenses decreased 15.4% to $294.1M.
• · Income from discontinued operations of $373.0M in FY2025 from Dermavant sale.

20-05-2026

Immunovant reported its Q4 and FY2026 financial results, highlighting promising preliminary data for IMVT-1402 in difficult-to-treat rheumatoid arthritis (D2T RA) with ACR20/50/70 response rates of 72.7%, 54.5%, and 35.8% at Week 16. The company ended the quarter with $902.1M in cash, providing runway to the potential launch of IMVT-1402 in Graves' disease. However, net loss widened to $147.9M for Q4 FY2026 (up 39% YoY) and $505.6M for the full year (up 22% YoY), driven by increased R&D spending including $39M in costs related to the discontinuation of batoclimab after two Phase 3 TED studies failed to meet their primary endpoints.

• · ACR20/50/70 response rates at Week 16 in D2T RA trial: 72.7%, 54.5%, 35.8% (non-responder imputation for dropouts)
• · In the subset of patients who failed both a JAK inhibitor and anti-TNF inhibitor (N=107): ACR20 72.0%, ACR50 53.3%, ACR70 37.4%
• · Baseline disease activity: mean 24.2 tender joints, 16.7 swollen joints, DAS28-CRP score of 6.1; mean time since diagnosis 12.8 years
• · 86.7% (143/165) of evaluable patients had failed two prior mechanisms of advanced therapies
• · Non-GAAP R&D expenses Q4 FY2026: $136.0M (vs $87.2M in Q4 FY2025); Non-GAAP net loss Q4 FY2026: $137.0M (vs $94.9M)
• · Non-GAAP R&D expenses FY2026: $426.9M (vs $333.9M FY2025); Non-GAAP net loss FY2026: $449.9M (vs $364.7M)
• · Non-cash stock-based compensation: $11.1M in Q4 FY2026 ($55.7M full year) vs $11.7M in Q4 FY2025 ($49.5M full year)
• · Weighted-average shares outstanding (basic/diluted) for FY2026: 182,421,233 vs 151,573,553 in FY2025
• · Topline data from potentially registrational trials in GD and MG expected in calendar year 2027
• · CLE proof-of-concept trial fully enrolled, topline data expected H2 2026
• · Immunovant discontinued batoclimab after two Phase 3 TED studies failed primary endpoint; safety profile consistent with prior studies

20-05-2026

Vaxart, Inc. filed a DEFA14A soliciting material in connection with its 2026 Annual Meeting of Stockholders. The filing identifies the company's directors and executive officers as participants in the proxy solicitation and directs stockholders to read the definitive proxy statement when available. No specific financial results or operational metrics are disclosed in this filing.

• · The filing is a soliciting material pursuant to Rule 14a-12 under the Securities Exchange Act of 1934.
• · Stockholders are directed to obtain the definitive proxy statement at no charge from the SEC's website (www.sec.gov) or the company's investor relations website.
• · Supplemental information regarding participants' holdings of the company's securities can be found in a Form 4 filed on May 1, 2026 with respect to Dr. Breitmeyer.

20-05-2026

CCM Investment Advisers LLC filed its 13F-HR for the quarter ended March 31, 2026, reporting a total portfolio value of approximately $1.04 billion across 93 equity holdings. The largest positions include AbbVie, Alphabet Inc. Class A, Amazon, Apple, Applied Materials, Broadcom, Caterpillar, Jabil Circuit, NVIDIA, Netflix, and Seagate Technology, indicating a diversified portfolio with significant exposure to technology and healthcare sectors.

• · The filing was signed by Richard J. Linden, President of CCM Investment Advisers LLC.
• · The portfolio includes 93 equity positions with a total market value of $1,044,670,777 as of March 31, 2026.
• · Top holdings by value include AbbVie ($15.4M), Alphabet Class A ($38.0M), Amazon ($30.8M), Apple ($31.4M), Applied Materials ($28.9M), Broadcom ($30.8M), Caterpillar ($34.6M), Jabil Circuit ($33.0M), NVIDIA ($36.4M), Netflix ($24.0M), and Seagate Technology ($36.0M).
• · The portfolio also includes preferred stocks in Apollo, Bank of America, Public Storage, and US Bancorp, as well as money market funds from Schwab and Victory.
• · All reported securities are held with sole voting and dispositive power.

20-05-2026

Victoria's Secret & Co. released definitive additional proxy materials on May 20, 2026, featuring video transcripts from board chairs detailing the company's transformation under CEO Hillary Super. The board emphasizes early momentum from the 'Path to Potential' strategy, including a sharper positioning of the PINK brand, but acknowledges the transformation is still early and significant opportunity remains. The filing highlights board refreshment (three new independent directors since 2022), 80% female board composition, and a pay-for-performance compensation framework aligned with long-term strategic goals.

• · The board has added three independent directors since 2022, bringing expertise in strategic planning, M&A, e-commerce, and digital operations.
• · 80% of the board directors are women, reflecting the predominantly female customer base.
• · The compensation framework now includes strategic initiatives from the Path to Potential plan, not just near-term financial metrics.
• · Donna James has served on at least nine public company boards; Irene Chang Britt has served on seven.
• · Anne Sheehan previously served as Director of Corporate Governance for CalSTRS, one of the world's largest institutional investors.

20-05-2026

On May 19, 2026, Appalachian Power Recovery Funding LLC (Issuing Entity) and Appalachian Power Company (APCo) entered into an Underwriting Agreement with Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, and RBC Capital Markets, LLC to issue $1,375,500,000 aggregate principal amount of Series 2026-A Senior Secured SAC Bonds. The agreement includes customary representations, warranties, and indemnification provisions, with closing expected on May 27, 2026. No financial performance metrics are reported.

• · The bonds are issued under an Indenture and Series Supplement dated May 27, 2026, and offered via a prospectus dated May 19, 2026.
• · Additional agreements to be entered into on May 27, 2026 include a Servicing Agreement, Purchase and Sale Agreement, Administration Agreement, and Joinder to Intercreditor Agreement.
• · The Underwriting Agreement includes customary closing conditions and indemnification obligations for liabilities under the Securities Act of 1933.

20-05-2026

Soluna Holdings acquired the remaining 49% equity interest in Project Dorothy 1B from Navitas Global for approximately $8.8 million, achieving 100% ownership of the 50 MW campus. This acquisition, funded from balance sheet cash, completes the vertical integration of the Dorothy 1 campus following earlier acquisitions of the Briscoe Wind Farm ($53M) and Project Dorothy 1A ($16.5M), positioning the campus for conversion to AI and high-performance computing workloads. The company's development pipeline now exceeds 4.3 GW, including over 1 GW in development, construction, and operations.

• · Closing date of the acquisition was May 19, 2026.
• · The acquisition was financed using balance sheet cash.
• · Soluna is actively evaluating opportunities related to Dorothy 2 as part of its broader campus development strategy.
• · The company's development pipeline exceeds 4.3 GW, including more than 1 GW in development, construction, and operations.

20-05-2026

Juniata Valley Financial Corp. filed an 8-K on May 20, 2026, reporting that shareholders approved the 2026 Long-Term Incentive Plan at the annual meeting on May 19, 2026. The plan authorizes grants of incentive stock options, nonqualified stock options, stock appreciation rights, performance restricted shares, restricted stock awards, and stock awards to officers, directors, and key employees. No financial figures or period-over-period comparisons are included in this filing.

• · The 2026 Long-Term Incentive Plan was approved by shareholders on May 19, 2026.
• · The plan covers awards to officers, directors, and key employees.
• · Award types include incentive stock options, nonqualified stock options, stock appreciation rights, performance restricted shares, restricted stock awards, and stock awards.
• · The plan description is incorporated by reference from the definitive proxy statement filed March 26, 2026.

20-05-2026

Wheeler Real Estate Investment Trust, Inc. announced that interest on its 7.00% Subordinated Convertible Notes due 2031 payable on June 30, 2026 to holders of record as of June 1, 2026 will be paid in the form of Series D Cumulative Convertible Preferred Stock instead of cash. This decision reflects the company's ongoing capital management strategy.

• · Interest payment date: June 30, 2026
• · Record date: June 1, 2026 at 5:00 p.m. New York City time
• · Interest will be paid in Series D Cumulative Convertible Preferred Stock rather than cash

20-05-2026

Investcorp AI Acquisition Corp. (IVCAF) filed an 8-K on May 20, 2026, disclosing the adoption of a second amended and restated memorandum and articles of association for its subsidiary Libity, effective May 14, 2026. The amendments include provisions for a Business Combination, Class B Share conversion, and other corporate governance updates. The filing indicates the company is preparing for a potential business combination transaction.

• · The company's registered office is at Appleby Global Services (Cayman) Limited, Suite 210, 2nd Floor Windward III, Regatta Office Park, PO Box 500, Grand Cayman, Cayman Islands KY1-1106.
• · The company has unrestricted objects and corporate capacity under Cayman Islands law.
• · The company is limited by shares, with liability of members limited to unpaid amounts on shares.
• · The company has power to redeem or repurchase shares, increase or reduce capital, and issue shares with special rights.
• · The company may register by way of continuation in another jurisdiction.
• · The articles include provisions for a Business Combination (Article 36) and Class B Share conversion (Article 37).
• · The Class B Share Entitlement gives the Sponsor 20% of all entitlements to income and capital.
• · Fair Value for a Business Combination is defined as at least 80% of a specified value.

20-05-2026

West Pharmaceutical Services filed an 8-K/A amendment disclosing that a material cybersecurity attack was detected on May 4, 2026, with data exfiltration and system encryption. The company has restored core systems, resumed manufacturing and shipping at all sites, and is now fully operational globally; no unauthorized activity has been observed since May 5, 2026. Based on the investigation to date, the company believes the incident has not had and is not reasonably likely to have a material impact on its 2026 second-quarter and full-year financial guidance.

• · The cybersecurity incident involved data exfiltration by an unauthorized party and encryption of certain systems.
• · Initial detection of the intrusion occurred on May 4, 2026; the company promptly activated incident response protocols, including taking systems offline globally, notifying law enforcement, and engaging external cyber-forensic experts.
• · No unauthorized activity or access has been observed since May 5, 2026.
• · The company's investigation into the nature and scope of the incident is continuing, including regarding the extent of data affected.
• · The company believes the incident has not had and is not reasonably likely to have a material impact on its 2026 second-quarter and full-year financial guidance.

20-05-2026

ConnectOne Bancorp, Inc. held its Annual Meeting on May 19, 2026, where shareholders elected 15 directors, approved the 2026 Equity Incentive Plan, and ratified the independent auditor. The board also appointed Elizabeth Magennis as President of the Registrant, while Frank Sorrentino continues as Chairman and CEO. All proposals passed with strong support, though broker non-votes were significant at 6,162,210 shares.

• · Proposal 1: All 15 directors were elected with votes For ranging from 34,914,271 to 35,699,832; highest withheld votes were for Frank Huttle III (1,216,630) and Frank W. Baier (1,011,078).
• · Proposal 2 (2026 Equity Incentive Plan): 34,424,591 For, 1,648,967 Against, 57,343 Abstentions.
• · Proposal 3 (Advisory Say-on-Pay): 34,932,239 For, 774,603 Against, 424,059 Abstentions.
• · Proposal 4 (Ratification of Auditors): 41,871,092 For, 377,047 Against, 44,972 Abstentions — no broker non-votes as this is a routine matter.
• · Elizabeth Magennis was previously Executive Vice President of the Registrant and President of ConnectOne Bank; she will continue as President of the Bank and as a director of both entities.
• · Frank Sorrentino relinquished the President title but remains Chairman and CEO.

20-05-2026

Southside Bancshares Inc announces an amendment to its Restated Certificate of Formation, approved by shareholders and effective upon filing with the Texas Secretary of State. The amendment increases the authorized capital stock from a prior amount to 88,000,000 total shares, comprising 80,000,000 shares of common stock ($1.25 par value) and 8,000,000 shares of preferred stock (no par value). The filing provides standard authorization for the Board to designate series of preferred stock, with no financial results or period-over-period comparisons included.

• · First Amendment to Restated Certificate of Formation filed under Texas Business Organizations Code
• · Original formation date of the corporation: August 11, 1982 (file number 61819600)
• · Common stock par value set at $1.25 per share; preferred stock has no par value
• · Amendment became effective upon filing with the Texas Secretary of State on or around May 20, 2026
• · Board of Directors retains authority to designate series, preferences, and rights of preferred stock

20-05-2026

Five9, Inc. held its 2026 annual meeting on May 20, 2026, with 82% of outstanding shares represented. Stockholders approved proposals to declassify the Board of Directors and remove supermajority voting requirements, elected Amit Mathradas and Sagar Gupta as Class III directors, approved advisory executive compensation, and ratified KPMG LLP as auditor for FY2026. The advisory vote on executive compensation saw notable opposition (8.8% against), while director elections and governance proposals passed with overwhelming support.

• · Record date for the Annual Meeting was March 24, 2026
• · The board declassification and supermajority removal proposals each received over 55M shares FOR, with minimal opposition (<140K against each)
• · Amit Mathradas received 55,248,526 shares FOR (99.9% of votes cast excluding broker non-votes) compared to Sagar Gupta's 54,143,117 FOR (99.2%), indicating slightly higher support for Mathradas
• · Advisory executive compensation proposal received 4,964,172 shares AGAINST (8.8% of votes cast excluding abstentions), a notable level of dissent
• · KPMG LLP ratification received 62,448,505 shares FOR (99.6% of votes cast), near unanimous support

20-05-2026

Diamondback Energy announced the transition of Travis D. Stice from Executive Chairman to non-executive Chairman effective May 20, 2026, as part of a previously disclosed leadership plan. At the 2026 Annual Meeting, stockholders elected 13 directors, approved executive compensation on an advisory basis, and ratified Grant Thornton as auditor. The board also determined to hold future advisory votes on executive compensation annually.

• · Travis Stice received 245,001,012 votes for and 4,645,408 against his election as director.
• · Proposal 2 (advisory vote on executive compensation) received 245,941,011 votes for and 3,547,122 against.
• · Proposal 3 (frequency of advisory vote) resulted in 246,338,007 votes for 1 year, 371,078 for 2 years, and 2,888,098 for 3 years.
• · Proposal 4 (ratification of Grant Thornton) received 263,223,128 votes for and 1,308,991 against.
• · The next advisory vote on frequency of future advisory votes will be no later than the 2032 annual meeting.

20-05-2026

TREASURE GLOBAL INC (TGL) reported a net loss of $2.32M for Q3 FY2026 (three months ended March 31, 2026), compared to net income of $1.26M in the same quarter last year, driven by a sharp decline in gross profit to just $6,415 from $486,283. Revenue grew 125% YoY to $1.50M, but cost of revenues surged to $1.49M, nearly matching revenue. For the nine-month period, the net loss widened to $7.56M from a prior-year net income of $0.08M, while cash and cash equivalents increased significantly to $2.91M from $0.24M at June 30, 2025, primarily due to financing activities.

• · Total operating expenses for the three months ended March 31, 2026 were $4,192,751, up from $529,692 in the prior year period, driven largely by a $3,811,991 general and administrative expense.
• · The company recorded a long-lived assets impairment of $3,044,877 in the nine months ended March 31, 2026.
• · Allowance for credit losses was $3,434,741 for the nine months ended March 31, 2026, compared to $90,480 in the prior year period.
• · Net cash used in operating activities for the nine months ended March 31, 2026 was $5,191,149, improving from $5,817,360 in the prior year period.
• · The company issued 1,675,725 common shares as of March 31, 2026, up from 207,470 as of June 30, 2025, reflecting significant equity financing activities including share purchase agreements, direct offerings, and warrant exercises.
• · Derivative liabilities increased to $1,165,795 as of March 31, 2026 from $383,886 as of June 30, 2025.
• · The company had no intangible assets as of March 31, 2026, down from $3,044,877 as of June 30, 2025, due to impairment.
• · Basic and diluted loss per share was $(1.39) for the three months ended March 31, 2026, compared to income per share of $21.79 in the prior year period.
• · The company effected a 1-for-50 reverse stock split on April 7, 2025 and a 1-for-20 reverse stock split on December 5, 2025.

20-05-2026

Twin Vee PowerCats Co. delivered a notice of non-renewal to CEO Joseph Visconti, whose employment agreement will expire on July 23, 2026. After that date, Visconti will continue as CEO, Interim CFO, and President on an at-will basis. The non-renewal was not due to any disagreement.

• · The Employment Agreement was effective July 23, 2021.
• · The Initial Term expires on July 23, 2026.
• · The notice was delivered on May 17, 2026.
• · The filing was made on May 20, 2026.

20-05-2026

INOVIO PHARMACEUTICALS, INC. adopted amendments to its Amended and Restated Bylaws on May 19, 2026, primarily to clarify the roles and meeting presidencies of the Chairman of the Board, Lead Independent Director, Chief Executive Officer, and President. The amendments formalize the Lead Independent Director position with specific duties, including agenda setting and presiding over independent director meetings and CEO evaluation sessions. The changes also update the duties of the CEO and President, specifying their presiding roles in the absence of the Chairman and Lead Independent Director.

• · The amendment adds a new Section 3.11 to Article III, formally defining the Lead Independent Director role with seven specific duties.
• · Section 3.5(e) establishes a clear order of precedence for presiding over board meetings: Chairman, Lead Independent Director, CEO (if a director), President (if a director), or a chairman chosen by a majority of directors.
• · Section 3.10 clarifies that the Chairman of the Board is not automatically an officer unless expressly designated by the Board.
• · Section 4.2(b) and (c) update the duties of the CEO and President, including their presiding roles at stockholder and board meetings in the absence of the Chairman and Lead Independent Director.

20-05-2026

Onto Innovation Inc. held its 2026 Annual Meeting on May 20, 2026, where stockholders elected seven directors, approved advisory executive compensation, and ratified Ernst & Young LLP as the independent auditor for fiscal year 2026. All proposals passed with strong majority support, though director David B. Miller received the lowest 'For' votes (38,775,556) with 3,185,107 against, indicating some shareholder dissent.

• · Proposal 1: All seven director nominees were elected; David B. Miller received the lowest 'For' votes (38,775,556) and highest 'Against' votes (3,185,107).
• · Proposal 2: Advisory executive compensation was approved with 40,624,022 'For', 1,196,481 'Against', and 201,194 'Abstain'.
• · Proposal 3: Ratification of Ernst & Young LLP as auditor passed with 44,378,549 'For', 178,157 'Against', and 147,375 'Abstain' (no broker non-votes).
• · Broker non-votes were 2,682,384 for Proposals 1 and 2, and 0 for Proposal 3.